Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70384 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Klaus W Fagerstedt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Ubiquitin-Protein Ligases, Tripartite Motif Proteins, Transcription Factors. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medicinska Understödsföreningen Liv och Hälsa, Finska Läkaresällskapet, Sigrid Juséliuksen Säätiö.
Abstract (Originalsprache)
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer, most often driven by integration of Merkel cell polyomavirus (MCPyV). While anti‐PD‐1/PD‐L1 therapies have improved outcomes, reliable prognostic biomarkers remain limited. Tripartite motif‐containing protein 25 (TRIM25), a critical activator of innate immunity, was evaluated here for its clinical and biological relevance in MCC. We analysed TRIM25 mRNA and protein expression in 102 MCC cases and 9 MCC cell lines, respectively, and assessed associations with MCPyV status, clinicopathological characteristics and patient survival. Differential gene expression analysis was performed to identify pathways associated with TRIM25 expression in both low and high TRIM25 ‐expressing tumour groups. High TRIM25 expression was significantly associated with MCPyV positivity in both patient tumours ( p = .004) and cell lines ( p = .016), and TRIM25 and MCPyV mRNA levels correlated positively in tumours ( r = 0.264, p = .013). Patients with low TRIM25 expression had a significantly poorer 5‐year disease‐specific survival than those with high expression (53% vs. 78%, p = .013). Notably, Cox multivariate analysis confirmed that TRIM25 serves as an independent prognostic marker, irrespective of MCPyV status. Pathway analysis revealed that low TRIM25 expression was linked to antigen presentation pathways, while high TRIM25 expression was associated with cell cycle regulation. Our findings suggest that TRIM25 serves as a valuable prognostic biomarker in MCC. Additionally, TRIM25 may play a pathogenic role in MCPyV‐positive tumours, warranting further investigation to elucidate its mechanistic involvement in MCC tumourigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Molecular and Integrative Biosciences Research Programme, University of Helsinki, Helsinki, Finland.
- HUS Diagnostic Centre, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Klaus W Fagerstedt, Benjamin Z Sundqvist, Harri Sihto
Förderung
- Medicinska Understödsföreningen Liv och Hälsa
- Finska Läkaresällskapet
- Sigrid Juséliuksen Säätiö
- Syöpäsäätiö
Zitieren
APA
Fagerstedt, K. W., Kilpinen, S., Arola, J., Sundqvist, B. Z., Böhling, T., Andersson, L. C., & Sihto, H. (2026). Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status. International Journal of Cancer. https://doi.org/10.1002/ijc.70384
Vancouver
Fagerstedt KW, Kilpinen S, Arola J, Sundqvist BZ, Böhling T, Andersson LC, et al. Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status. International Journal of Cancer. 2026. doi:10.1002/ijc.70384
BibTeX
@article{Fagerstedt2026,
author = {Fagerstedt, Klaus W and Kilpinen, Sami and Arola, Johanna and Sundqvist, Benjamin Z and Böhling, Tom and Andersson, Leif C and Sihto, Harri},
title = {Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70384}
}
EUVIMED